Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2024-03-01
2024-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dexmedetomidine Ropivacaine Versus Plain Ropivacaine in Bilateral Pectoralis Nerve (PECS) Block
NCT06636578
PECS Block With Bupivacaine Vs Bupivacaine and Dexmedetomidine in Modified Radical Mastectomy
NCT04284098
General Anesthesia and Paravertebral Blocks vs. General Anesthesia Only: Influence Inflammation Factors and Clinical Outcomes in Modified Radical Mastectomy
NCT04540055
Ultrasound-guided Serratus Plane Block for the Quality of Recovery After Modified Radical Mastectomy
NCT02691195
Regional Anesthesia and Partial Mastectomy
NCT04824599
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PECS
PECS II block before surgery using isobaric bupivacaine 0.25% 20 mL (50 mg)
PECS II block
Treatment group that received the PECS II block using isobaric bupivacaine 0.5% 50 mg
LIA
Local infiltration anesthesia after completion of surgery using isobaric bupivacaine 0.25% 20 mL (50 mg)
LIA
Treatment group that received the local infiltration anesthesia using isobaric bupivacaine 0.5% 50 mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PECS II block
Treatment group that received the PECS II block using isobaric bupivacaine 0.5% 50 mg
LIA
Treatment group that received the local infiltration anesthesia using isobaric bupivacaine 0.5% 50 mg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Body weight (BW): 50-70 kg.
3. Height (TB): 150-170 cm.
4. Body mass index (BMI): 18.5-29.9 kg/m2.
5. American Society of Anesthesiologists physical status (ASA PS) class I-II.
6. Patients undergoing elective MRM surgery under general anesthesia.
Exclusion Criteria
2. Patients with contraindications to LIA.
3. Patients with coagulation disorders or receiving anticoagulant therapy.
4. Patients with a history of chronic pain.
5. Patients with a history of allergy to study materials.
6. Patients with a history of previous breast surgery.
7. Patient refuses to participate in the study.
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hasanuddin University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jokevin Prasetyadhi
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
RSUP dr. Wahidin Sudirohusodo
Makassar, South Sulawesi, Indonesia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
173/UN4.6.4.5.31/PP36/2AZ4
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.